Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody: An indicator of poor prognosis
✍ Scribed by Richard H. T. Loke; Dr. Iain M. Murray-Lyon; John C. Coleman; Brian A. Evans; Arie J. Zuckerman
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 311 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Three doses of a recombinant DNA HBV vaccine (MSD) were given to healthy male homosexuals. Seventy‐eight out of 104 (77.6%) participants had detectable antibody (anti‐HBs) two months after the third dose. Seroconversion occurred in only 9 out of 27 subjects (33.3%) who were anti‐HIV positive compared with 69 out of 77 (89.6%) who were negative (χ^2^ = 30.8; P < .001). Fifteen of the 18 anti‐HIV positive who did not mount an antibody response to the hepatitis B vaccine (anti‐HBs) later progressed to persistent generalised lymphadenopathy syndrome (5), AIDS‐related complex (5), and AIDS (5). Only one of the nine anti‐HIV positive anti‐HBs responders developed PGL (χ^2^ = 10.14; P < .005).
Our results show that anti‐HIV positive homosexuals are poor responders to the recombinant hepatitis B vaccine and anti‐HIV positive non‐responders are more likely to develop clinically apparent HIV infection.